, and REFORM trials (Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus) were 61.2 g/m2 (± 16.1 g/m2), 67.9 g/m2 (± 17.8 g/m2), and 69.5 g/m2 (± 16.3 g/m2) in the SGLT2i arms and 65.4 g/m2 (± 19.6), 65.9 g/m2 (± 19.8), and 73.7 g/m2 (± 19.3) in the placebo arms, respectively [26–28]. This evidence concerns the gene SLC5A2 and diabetes mellitus.